Report cover image

Oral Mucositis Market Size, Share & Trends Analysis Report By Treatment (Growth Factor, Barrier, Topical Analgesics, Cryotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Oct 20, 2025
Length 125 Pages
SKU # GV20575115

Description

Oral Mucositis Market Summary

The global oral mucositis market size was estimated at USD 1.50 billion in 2024 and is projected to reach USD 2.85 billion by 2033, growing at a CAGR of 7.35% from 2025 to 2033. The rising clinical burden of Oral Mucositis (OM) is one of the major factors driving the market growth for oral mucositis.

OM is a frequent complication of chemotherapy and radiotherapy, and increasing cancer treatment further impacts the OM market positively. In addition, the growing awareness of supportive care options and the need to improve patients’ quality of life during cancer treatment are boosting market demand. Continuous research and development in preventive and therapeutic interventions for oral mucositis is also driving the market’s growth.

Increasing cases of cancer day by day are driving growth in the oral mucositis industry. The World Health Organization (WHO) projects over 35 million new cancer cases by 2050, a 77% increase from an estimated 20 million cases in 2022, reflecting both population aging and growth. This increase leads to a larger number of patients undergoing chemotherapy and radiotherapy, which frequently results in oral mucositis as a side effect. Furthermore, improvements in cancer therapies have enhanced survival rates, expanding the population requiring supportive care. Demand for effective oral mucositis treatments is increasing, and the market is growing.

Advancements in regular clinical assessment and management guidelines support oral mucositis treatment. In June 2024, the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) released updated guidance recommending the WHO Oral Toxicity Scale for OM assessment in clinical trials. This global standard assists in standardizing assessment within various evaluation environments, such as radiotherapy and hematopoietic stem cell transplantation (HSCT). These guidelines will help ensure better patient monitoring, accelerate the development of new treatments, and promote effective OM interventions more widely, which is expected to drive market growth.

Global Oral Mucositis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oral mucositis market report based on treatment, distribution channel, and region:
  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Growth factor / Epithelial Protective Agents
  • Barrier/ Coating Gels and Rinses
  • Topical analgesics
  • Cryotherapy
  • Low-level Laser/ Photobiomodulation therapy (LLLT)
  • Antimicrobials
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
    • Please note The report will be delivered in 2-3 business days upon order notification.

    Table of Contents

    125 Pages
    Chapter 1. Methodology and Scope
    1.1. Market Segmentation & Scope
    1.2. Segment Definitions
    1.2.1. Treatment
    1.2.2. Distribution Channel
    1.3. Estimates and Forecast Timeline
    1.4. Research Methodology
    1.5. Information Procurement
    1.5.1. Purchased Database
    1.5.2. GVR’s Internal Database
    1.5.3. Secondary Sources
    1.5.4. Primary Research
    1.6. Information Analysis
    1.6.1. Data Analysis Models
    1.7. Market Formulation & Data Visualization
    1.8. Model Details
    1.8.1. Commodity Flow Analysis
    1.9. List of Secondary Sources
    1.10. Objectives
    Chapter 2. Executive Summary
    2.1. Market Snapshot
    2.2. Segment Snapshot
    2.3. Competitive Landscape Snapshot
    Chapter 3. Oral Mucositis Market Variables, Trends, & Scope
    3.1. Market Lineage Outlook
    3.2. Market Dynamics
    3.2.1. Market Driver Analysis
    3.2.2. Market Restraint Analysis
    3.3. Business Environment Analysis
    3.3.1. Industry Analysis - Porter’s Five Forces Analysis
    3.3.1.1. Supplier Power
    3.3.1.2. Buyer Power
    3.3.1.3. Substitution Threat
    3.3.1.4. Threat of New Entrants
    3.3.1.5. Competitive Rivalry
    3.3.2. PESTLE Analysis
    Chapter 4. Oral Mucositis Market: Treatment Business Analysis
    4.1. Treatment Market Share, 2024 & 2033
    4.2. Treatment Segment Dashboard
    4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
    4.4. Growth Factor /Epithelial Protective Agents
    4.4.1. Growth Factor /Epithelial Protective Agents Market, 2021 - 2033 (USD Million)
    4.5. Barrier/Coating Gels and Rinses
    4.5.1. Barrier/Coating Gels and Rinses Market, 2021 - 2033 (USD Million)
    4.6. Topical Analgesics
    4.6.1. Topical Analgesics Market, 2021 - 2033 (USD Million)
    4.7. Cryotherapy
    4.7.1. Cryotherapy Market, 2021 - 2033 (USD Million)
    4.8. Low-level Laser/Photobiomodulation Therapy (LLLT)
    4.8.1. Low-level Laser/Photobiomodulation Therapy Market, 2021 - 2033 (USD Million)
    4.9. Antimicrobials
    4.9.1. Antimicrobials Market, 2021 - 2033 (USD Million)
    Chapter 5. Oral Mucositis Market: Distribution Channel Business Analysis
    5.1. Distribution Channel Market Share, 2024 & 2033
    5.2. Distribution Channel Segment Dashboard
    5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
    5.4. Hospital Pharmacies
    5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
    5.5. Retail Pharmacies
    5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
    5.6. Other
    5.6.1. Other Market, 2021 - 2033 (USD Million)
    Chapter 6. Oral Mucositis Market: Regional Estimates & Trend Analysis
    6.1. Regional Market Share Analysis, 2024 & 2033
    6.2. Regional Market Dashboard
    6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
    6.4. North America
    6.4.1. North America Oral Mucositis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    6.4.2. U.S.
    6.4.2.1. Key Country Dynamics
    6.4.2.2. Type Disease Prevalence
    6.4.2.3. Regulatory Framework
    6.4.2.4. Reimbursement Framework
    6.4.2.5. U.S. Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.4.3. Canada
    6.4.3.1. Key Country Dynamics
    6.4.3.2. Type Disease Prevalence
    6.4.3.3. Regulatory Framework
    6.4.3.4. Reimbursement Framework
    6.4.3.5. U.S. Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.4.4. Mexico
    6.4.4.1. Key Country Dynamics
    6.4.4.2. Type Disease Prevalence
    6.4.4.3. Regulatory Framework
    6.4.4.4. Reimbursement Framework
    6.4.4.5. Mexico Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.5. Europe
    6.5.1. Europe Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.5.2. UK
    6.5.2.1. Key Country Dynamics
    6.5.2.2. Type Disease Prevalence
    6.5.2.3. Regulatory Framework
    6.5.2.4. Reimbursement Framework
    6.5.2.5. Uk Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.5.3. Germany
    6.5.3.1. Key Country Dynamics
    6.5.3.2. Type Disease Prevalence
    6.5.3.3. Regulatory Framework
    6.5.3.4. Reimbursement Framework
    6.5.3.5. Germany Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.5.4. France
    6.5.4.1. Key Country Dynamics
    6.5.4.2. Type Disease Prevalence
    6.5.4.3. Regulatory Framework
    6.5.4.4. Reimbursement Framework
    6.5.4.5. France Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.5.5. Italy
    6.5.5.1. Key Country Dynamics
    6.5.5.2. Type Disease Prevalence
    6.5.5.3. Regulatory Framework
    6.5.5.4. Reimbursement Framework
    6.5.5.5. Italy Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.5.6. Spain
    6.5.6.1. Key Country Dynamics
    6.5.6.2. Type Disease Prevalence
    6.5.6.3. Regulatory Framework
    6.5.6.4. Reimbursement Framework
    6.5.6.5. Spain Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.5.7. Denmark
    6.5.7.1. Key Country Dynamics
    6.5.7.2. Type Disease Prevalence
    6.5.7.3. Regulatory Framework
    6.5.7.4. Reimbursement Framework
    6.5.7.5. Denmark Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.5.8. Sweden
    6.5.8.1. Key Country Dynamics
    6.5.8.2. Type Disease Prevalence
    6.5.8.3. Regulatory Framework
    6.5.8.4. Reimbursement Framework
    6.5.8.5. Sweden Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.5.9. Norway
    6.5.9.1. Key Country Dynamics
    6.5.9.2. Type Disease Prevalence
    6.5.9.3. Regulatory Framework
    6.5.9.4. Reimbursement Framework
    6.5.9.5. Norway Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.6. Asia Pacific
    6.6.1. Asia Pacific Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.6.2. Japan
    6.6.2.1. Key Country Dynamics
    6.6.2.2. Type Disease Prevalence
    6.6.2.3. Regulatory Framework
    6.6.2.4. Reimbursement Framework
    6.6.2.5. Japan Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.6.3. China
    6.6.3.1. Key Country Dynamics
    6.6.3.2. Type Disease Prevalence
    6.6.3.3. Regulatory Framework
    6.6.3.4. Reimbursement Framework
    6.6.3.5. China Oral MucositisMarket Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.6.4. India
    6.6.4.1. Key Country Dynamics
    6.6.4.2. Type Disease Prevalence
    6.6.4.3. Regulatory Framework
    6.6.4.4. Reimbursement Framework
    6.6.4.5. India Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.6.5. Australia
    6.6.5.1. Key Country Dynamics
    6.6.5.2. Type Disease Prevalence
    6.6.5.3. Regulatory Framework
    6.6.5.4. Reimbursement Framework
    6.6.5.5. Australia Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.6.6. South Korea
    6.6.6.1. Key Country Dynamics
    6.6.6.2. Type Disease Prevalence
    6.6.6.3. Regulatory Framework
    6.6.6.4. Reimbursement Framework
    6.6.6.5. South Korea Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.6.7. Thailand
    6.6.7.1. Key Country Dynamics
    6.6.7.2. Type Disease Prevalence
    6.6.7.3. Regulatory Framework
    6.6.7.4. Reimbursement Framework
    6.6.7.5. Thailand Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.7. Latin America
    6.7.1. Latin America Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.7.2. Brazil
    6.7.2.1. Key Country Dynamics
    6.7.2.2. Type Disease Prevalence
    6.7.2.3. Regulatory Framework
    6.7.2.4. Reimbursement Framework
    6.7.2.5. Japan Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.7.3. Argentina
    6.7.3.1. Key Country Dynamics
    6.7.3.2. Type Disease Prevalence
    6.7.3.3. Regulatory Framework
    6.7.3.4. Reimbursement Framework
    6.7.3.5. China Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.8. Middle East and Africa
    6.8.1. Middle East and Africa Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.8.2. South Africa
    6.8.2.1. Key Country Dynamics
    6.8.2.2. Type Disease Prevalence
    6.8.2.3. Regulatory Framework
    6.8.2.4. Reimbursement Framework
    6.8.2.5. South Africa Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.8.3. Saudi Arabia
    6.8.3.1. Key Country Dynamics
    6.8.3.2. Type Disease Prevalence
    6.8.3.3. Regulatory Framework
    6.8.3.4. Reimbursement Framework
    6.8.3.5. Saudi Arabia Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.8.4. UAE
    6.8.4.1. Key Country Dynamics
    6.8.4.2. Type Disease Prevalence
    6.8.4.3. Regulatory Framework
    6.8.4.4. Reimbursement Framework
    6.8.4.5. UAE Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    6.8.5. Kuwait
    6.8.5.1. Key Country Dynamics
    6.8.5.2. Type Disease Prevalence
    6.8.5.3. Regulatory Framework
    6.8.5.4. Reimbursement Framework
    6.8.5.5. Kuwait Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    Chapter 7. Competitive Landscape
    7.1. Participant Overview
    7.2. Company Market Position Analysis
    7.3. Company Categorization
    7.4. Strategy Mapping
    7.5. Company Profiles/Listing
    7.5.1. Amgen Inc.
    7.5.1.1. Overview
    7.5.1.2. Financial Performance
    7.5.1.3. Product Benchmarking
    7.5.1.4. Strategic Initiatives
    7.5.2. EpicentRx, Inc.
    7.5.2.1. Overview
    7.5.2.2. Financial Performance
    7.5.2.3. Product Benchmarking
    7.5.2.4. Strategic Initiatives
    7.5.3. Pfizer Inc.
    7.5.3.1. Overview
    7.5.3.2. Financial Performance
    7.5.3.3. Product Benchmarking
    7.5.3.4. Strategic Initiatives
    7.5.4. Soleva Pharma, LLC.
    7.5.4.1. Overview
    7.5.4.2. Financial Performance
    7.5.4.3. Product Benchmarking
    7.5.4.4. Strategic Initiatives
    7.5.5. Basic Pharma Life Science Pvt Ltd.
    7.5.5.1. Overview
    7.5.5.2. Financial Performance
    7.5.5.3. Product Benchmarking
    7.5.5.4. Strategic Initiatives
    7.5.6. CANbridge Pharmaceuticals Inc.
    7.5.6.1. Overview
    7.5.6.2. Financial Performance
    7.5.6.3. Product Benchmarking
    7.5.6.4. Strategic Initiatives
    7.5.7. Enzychem Lifesciences Corporation
    7.5.7.1. Overview
    7.5.7.2. Financial Performance
    7.5.7.3. Product Benchmarking
    7.5.7.4. Strategic Initiatives
    7.5.8. Galera Therapeutics, Inc.
    7.5.8.1. Overview
    7.5.8.2. Financial Performance
    7.5.8.3. Product Benchmarking
    7.5.8.4. Strategic Initiatives
    7.5.9. Helsinn Healthcare SA.
    7.5.9.1. Overview
    7.5.9.2. Financial Performance
    7.5.9.3. Product Benchmarking
    7.5.9.4. Strategic Initiatives
    7.5.10. Monopar Therapeutics, Inc.
    7.5.10.1. Overview
    7.5.10.2. Financial Performance
    7.5.10.3. Product Benchmarking
    7.5.10.4. Strategic Initiatives
    7.5.11. Swedish Orphan Biovitrum AB
    7.5.11.1. Overview
    7.5.11.2. Financial Performance
    7.5.11.3. Product Benchmarking
    7.5.11.4. Strategic Initiatives
    7.5.12. Innovation Pharmaceuticals Inc.
    7.5.12.1. Overview
    7.5.12.2. Financial Performance
    7.5.12.3. Product Benchmarking
    7.5.12.4. Strategic Initiatives

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Request A Sample
    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us